VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | Is it possible to achieve TFR with low-dose TKI therapy?

Giuseppe Saglio, MD, University of Turin, Turin, Italy, discusses the possibility of achieving treatment-free remission (TFR) with low-dose tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML). According to Prof. Saglio, whilst the recommended dose of imatinib should not be reduced, it may be possible to give a lower dose of second or third-generation TKIs. Alternatively, combining two TKIs in a lower dose could help maintain treatment efficacy while decreasing the toxicity of single TKIs. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter